 |
 |
 |
Management and BoardManagement
Board
|
David Knowles (Chief Scientific Officer) Board member
In 1999, he joined the board of RiboTargets plc and served as CSO for over 3 years before becoming Director of R&D at British Biotech, where he oversaw the merger with Vernalis. David worked as an independent consultant for a number of Private Equity Investors from the UK, Europe and the USA before becoming CSO and R&D Director for Piramed Ltd. in 2005. He has served on the Scientific Advisory and Supervisory Boards of a number of biotech companies, including MerLion Pharmaceuticals and Axxima AG. He is a non-executive director of Procarta Biosystems. He is a past Member of Council of the American Society for Microbiology and is on the editorial board of Current Opinions in Microbiology.
David joined CellCentric in January 2009. |
David Knowles was awarded a PhD from the Department of Biochemistry, Imperial College of Science and Technology, London in 1977. He joined May & Baker, a division of Rhone Poulenc, to work on therapeutic approaches targeting bacterial adhesion. Since then, he established an international reputation in anti-infectives research and development and has worked in several major international pharmaceutical companies including Beecham Pharmaceuticals, Wellcome Research Laboratories and SmithKline Beecham. In 1995 he was appointed Director of Molecular Microbiology at SmithKline Beecham, based in Pennsylvania. He returned to the UK at the end of 1996 and gained useful experience in anti-infective development at SB before embarking on a career in the biotech sector.